Evidence map›Paper›PMID 39474417›Full record

ArticleFrontiers in immunology2024

Bibliometric and visualized analysis on global trends and hotspots of TAK1 in regulated cell death: 1999 to 2024.

Kun Huang, Ye He, Hao Wan, Xiao-Xia Ban, Xin-Yu Chen, Xi-Min Hu, Xin-Xing Wan, Rui Lu, Qi Zhang, Kun Xiong

Abstract read
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Kun Huang *Department of Human Anatomy and Neurobiology, School of Basic Medical Science, Central South University, Changsha, China.
Ye He *Department of Human Anatomy and Neurobiology, School of Basic Medical Science, Central South University, Changsha, China.
Hao WanDepartment of Human Anatomy and Neurobiology, School of Basic Medical Science, Central South University, Changsha, China.
Xiao-Xia BanDepartment of Human Anatomy and Neurobiology, School of Basic Medical Science, Central South University, Changsha, China.
Xin-Yu ChenDepartment of Human Anatomy and Neurobiology, School of Basic Medical Science, Central South University, Changsha, China.
Xi-Min HuDepartment of Human Anatomy and Neurobiology, School of Basic Medical Science, Central South University, Changsha, China.
Xin-Xing WanDepartment of Endocrinology, Third Xiangya Hospital, Central South University, Changsha, China.
Rui LuDepartment of Molecular and Cellular Physiology, Stanford University, Stanford, CA, United States.
Qi ZhangDepartment of Human Anatomy and Neurobiology, School of Basic Medical Science, Central South University, Changsha, China.
Kun XiongDepartment of Human Anatomy and Neurobiology, School of Basic Medical Science, Central South University, Changsha, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Regulated cell death (RCD) is a genetically controlled form of cell death that plays an important role in organogenesis, tissue remodeling, and pathogenesis of cancers. Transforming growth factor-beta-activation kinase 1 (TAK1) is a member of the serine/threonine protein kinase family, which can respond to internal and external stimuli and participate in inflammatory responses through multiple signaling pathways and cellular processes. In the last two decades, the regulatory roles of TAK1 at the crossroads of multiple RCD pathways, including apoptosis, necroptosis, pyroptosis, and PANoptosis were revealed by 801 articles retrieved from the Web of Science Core Collection database. To analyze global research trends and hotspots concerning the role of TAK1 in RCD, the bibliometric and visualized analysis were applied in the current study. Methods: The data for this bibliometrics study were retrieved from the Web of Science Core Collection database. The search formula was (TS=(Apoptosis) OR TS=(pyroptosis) OR TS=(Necroptosis) OR TS=(PANoptosis) OR TS=(Autophagy) OR TS=(Ferroptosis) OR TS=(cuproptosis)) AND ((TS=(TAK1)) OR TS=(MAP3K7)). The co-occurrence and co-cited analysis on basic bibliometric parameters were conducted by VOSviewer. The dual-map overlay of journals, citation bursts, keyword timelines, and keyword bursts were analyzed by CiteSpace. Results: A total of 801 articles from 46 countries have been included in the analysis. The number of publications demonstrates a consistent increase from 1999 to 2024. The primary research institutions driving this field are Osaka University Notably, the Journal of Biological Chemistry stands out as the most popular journal in this domain. These publications collectively involve contributions from 4663 authors, with Jun Tsuji emerging as a prolific author. Jun Tsuji also gains the highest co-citation frequency. Emerging research hotspots are encapsulated by keywords, including apoptosis, NF-κB, inflammation, autophagy, and TNFα. Conclusion: This is the first bibliometric and visualized study to analyze the global trends and hotspots of TAK1 in RCD. Based on the analysis of 801 articles, the results provide a retrospective and comprehensive visualized view of the research hotspots and frontiers of TAK1 at the crossroads of multiple RCD signaling pathways and propose ideas for guiding their future investigations in molecular mechanisms and therapeutic strategies in this field.

Indexed as

BibliometricsMAP Kinase Kinase KinasesAnimalsApoptosisAutophagyCell DeathHumansMAP Kinase Kinase Kinase 7Signal TransductionMAP Kinase Kinase Kinase 7MAP Kinase Kinase Kinasesbibliometric analysiscancerCiteSpacenecroptosisPANoptosisregulated cell deathTAK1VOSviewer

Identifiers

PMID39474417
PMCPMC11518718

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.